Y-Intercept (HK)’s iBio IBIO Stock Holding History

Y-Intercept (HK)’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-72	Closed	-$10K	–	1107
2022 Q2	$10K	Buy	+72	New	+$10.8K	﹤0.01%	813

Other funds holding IBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Y-Intercept (HK)'s IBIO Position: Q3 2022 in Review

Y-Intercept (HK) sold out of iBio (IBIO) in Q3 2022, closing a stake of 72 shares — an estimated $10K sold.

Y-Intercept (HK) first reported a position in IBIO in Q2 2022 and held it in 1 quarter. The position peaked at $10K in Q2 2022. 43 funds tracked by Wall St. Rank hold IBIO as of Q3 2022.

Y-Intercept (HK) reported no remaining iBio position as of Q3 2022 after selling out during the quarter.
Y-Intercept (HK) sold 72 iBio shares in Q3 2022, an estimated $10K.
Y-Intercept (HK) first reported a position in iBio in Q2 2022 and held it in 1 quarter.
Y-Intercept (HK)'s iBio position peaked at $10K in Q2 2022.
43 funds tracked by Wall St. Rank held iBio as of Q3 2022.

Based on Y-Intercept (HK)'s 13F filing for Q3 2022, filed 14 Feb 2023.